These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 32205484)
21. SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia. Chapel DB; Hirsch MS Am J Surg Pathol; 2022 Feb; 46(2):213-219. PubMed ID: 34411029 [TBL] [Abstract][Full Text] [Related]
22. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Ordóñez NG Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794 [TBL] [Abstract][Full Text] [Related]
23. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms. Attanoos RL; Dojcinov SD; Webb R; Gibbs AR Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698 [TBL] [Abstract][Full Text] [Related]
24. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Muller S; Victoria Lai W; Adusumilli PS; Desmeules P; Frosina D; Jungbluth A; Ni A; Eguchi T; Travis WD; Ladanyi M; Zauderer MG; Sauter JL Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897 [TBL] [Abstract][Full Text] [Related]
25. D2-40: a reliable marker in the diagnosis of pleural mesothelioma. Müller AM; Franke FE; Müller KM Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Yaziji H; Battifora H; Barry TS; Hwang HC; Bacchi CE; McIntosh MW; Kussick SJ; Gown AM Mod Pathol; 2006 Apr; 19(4):514-23. PubMed ID: 16554731 [TBL] [Abstract][Full Text] [Related]
27. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Ordóñez NG Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246 [TBL] [Abstract][Full Text] [Related]
28. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma. Miettinen M; Limon J; Niezabitowski A; Lasota J Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772 [TBL] [Abstract][Full Text] [Related]
29. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations. Salisbury T; Churg A Virchows Arch; 2021 Nov; 479(5):1047-1050. PubMed ID: 33721119 [TBL] [Abstract][Full Text] [Related]
30. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Chu AY; Litzky LA; Pasha TL; Acs G; Zhang PJ Mod Pathol; 2005 Jan; 18(1):105-10. PubMed ID: 15389250 [TBL] [Abstract][Full Text] [Related]
31. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung. Berg KB; Churg A Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203 [TBL] [Abstract][Full Text] [Related]
32. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Ordóñez NG Hum Pathol; 2005 Apr; 36(4):372-80. PubMed ID: 15891998 [TBL] [Abstract][Full Text] [Related]
33. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
34. Frequent expression of conventional endothelial markers in pleural mesothelioma: usefulness of claudin-5 as well as combined traditional markers to distinguish mesothelioma from angiosarcoma. Nakashima Y; Inamura K; Ninomiya H; Okumura S; Mun M; Kirimura S; Kobayashi M; Okubo K; Ishikawa Y Lung Cancer; 2020 Oct; 148():20-27. PubMed ID: 32777673 [TBL] [Abstract][Full Text] [Related]
35. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Ordóñez NG Am J Surg Pathol; 2003 Aug; 27(8):1031-51. PubMed ID: 12883236 [TBL] [Abstract][Full Text] [Related]
36. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Attanoos RL; Webb R; Dojcinov SD; Gibbs AR Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489 [TBL] [Abstract][Full Text] [Related]
37. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions. Derakhshan F; Ionescu D; Cheung S; Churg A Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000 [TBL] [Abstract][Full Text] [Related]
38. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis. Piao ZH; Zhou XC; Chen JY Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661 [TBL] [Abstract][Full Text] [Related]
39. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Comin CE; Saieva C; Messerini L Am J Surg Pathol; 2007 Aug; 31(8):1139-48. PubMed ID: 17667535 [TBL] [Abstract][Full Text] [Related]
40. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]